Clinical Advisory Board

Daniel D. Von Hoff, MD, F.A.C.P., University of Arizona, is currently Director of the University of Arizona Health Sciences Center�s Cancer Therapeutics Program and Professor of Medicine, Molecular Biology and Pathology at the Arizona College of Medicine. In addition he serves as Executive Vice President, Director of Translational Drug Development and head of Pancreatic Cancer Research at TGen. He is a previous President of the American Association for Cancer Research and Director of the Arizona Cancer Institute. He is also a founder of ILEX Oncology and Editor-in-Chief of Molecular Cancer Therapeutics.

James Abbruzzese, M.D. Anderson Cancer Center, is currently Chief of Gastrointestinal Oncology at M.D. Anderson Cancer Center. He is an internationally renowned expert in colorectal, pancreatic and liver cancers, experimental therapeutics for cancer and has been Principal Investigator on virotherapy clinical trials.

Lawrence Shulman, MD, Dana-Farber Cancer Institute, is currently Chief Medical Officer and Senior Vice President for Medical Affairs at the Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School. He previously served as clinical director of Hematology-Oncology at Brigham and Women's Hospital, Harvard Medical School. He received his M.D. from Harvard Medical School and trained in hematology-oncology at Harvard (Beth Israel Hospital).

Hartley Stern, MD, FRCS, FACS, The Ottawa Hospital Regional Cancer Centre, is the Vice President of The Ottawa Regional Cancer Centre and the Pronvincial Head of Surgical Oncology with Cancer Care, Ontario. Dr. Stern�s clinical focus is colorectal cancer. His provincial role is focused on improving the standard of cancer surgery in Ontario.

Scientific Advisory Board

Stephen J. Russell, MD, PhD, Mayo Clinic, is the Director of Molecular Medicine Program at Mayo Clinic, which is one of the leading groups in virotherapy. Dr. Russell previously held a faculty position in Hematology at Cambridge University and was co-founder of Cambridge Genetics.

David L. Bartlett, MD, is currently The Bernard Fisher Professor of Surgery and Chief of Surgical Oncology at the University of Pittsburgh. Dr. Bartlett has helped develop technique for deliveryof hyperthermia and chemotherapy directly to the peritoneal cavity as a recirculating perfusion. He has over fifty publications in the field of oncolytic pox viruses, pox virus engineering, clinical oncology and genetic therapy.

Geoffrey L. Smith, FRS, FMedSci, FIBiol, is a Wellcome Trust Principal Research Fellow and Ch Dept in the Division of Investigative Science, Medicined at Imperial College, London, UK. He is the head of the Department of Virology at the Faculty of Medicine of Imperial College. He has a particular interest in pox viruses, and he was awarded the 2005 Feldburg Foundation Prize in recognition of his research in pox viruses.

Mark J. Federspiel, PhD, Mayo Clinic Rochester, is a tenured faculty member of the Mayo Clinic. He helped develop Mayo Clinic Viral Vector Production Laboratory to provide large scale virus production and the capability to produce clinical grade gene and virus therapy. He has an extensive expertise in the development and use of retroviral vectors, virological assays and animal models.

Louis Siminovitch, PhD, DSc, CC, FRSC, FRS is a pioneer in human genetics and has helped establish internationally renowned programs exploring the roots of cancer in Ontario, Canada. Dr. Siminovitch has received a long list of scientific and other awards including many honorary degrees, among which are the Flavelle Gold Medal of the Royal Society of Canada (1978), the Gairdner Foundation Wightman Award (1981). He has been made both an Officer and Companion of the Order of Canada (1980, 1989), and was inducted into the Canadian Medical Hall of Fame in 1997.